Sun Pharma Advanced Research Company share news and announcements
NSE: SPARCBSE: 532872Pharmaceuticals & BiotechnologySmall Cap
Last close ₹171.77down ₹1.32 (0.76%)BSE ₹171.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹173.09.
52-week range of traded prices to 23 Oct 2026
₹108.00Low, 23 Mar 2026₹289.00High, 8 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹5,574 Cr778th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 3.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 18 May 2026
- 4.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 10 Aug 2026
- 118.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 84.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 18 May 2026
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,97,11238.6% delivered
Sun Pharma Advanced Research Company share news and announcements
583 announcements, routine notices left out, newest first. Page 9 of 12.
Mar 2016
7 Mar · Board meeting
Feb 2016
Jan 2016
Dec 2015
Nov 2015
Oct 2015
Sep 2015
Aug 2015
20 Aug · Legal
Clarification by Sun Pharma Advanced Research Company Limited Substantial increase in trading volumes have been observed in Sun Pharma Advanced Research Company Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sun Pharma Advanced Research Company Limited has vide its letter inter-alia stated, "we wish to confirm that there are no material information / announcement / development (including pending / unpublished announcement) that could have triggered the jump in volume."19 Aug · Updates
Members of the Exchange are hereby informed that 2864 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. August 21, 2015.4 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2015
Jun 2015
23 Jun · Updates
Members of the Exchange are hereby informed that 33776 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. June 25, 2015.
May 2015
5 May · Change in Company Secretary/Compliance Officer
Apr 2015
21 Apr · Board meeting
Interalia, to consider and take on record the Audited Financial Results of the Company for the year ended March 31, 2015.
Mar 2015
Jan 2015
20 Jan · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Sun Pharma Advanced Research Company Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sun Pharma Advanced Research Company Limited has vide its letter inter-alia stated," there is no event which will have a bearing on the performance / operations of the Company nor any price sensitive information of the Company which are reportable under clause 36 or any other clause of the listing agreement."16 Jan · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the third quarter ended December 31, 2014.
Dec 2014
Nov 2014
21 Nov · Updates
Members of the Exchange are hereby informed that 5710 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. November 25, 2014.
Oct 2014
31 Oct · Management
Board of Directors of the Company at its meeting held on October 31, 2014 has appointed Ms. Bhavna Doshi as an additional independent Director on the Board of Directors of the Company.17 Oct · Board meeting
Interalia to consider and take on record the Unaudited Financial Results of the Company for the second quarter / half year ended September 30, 2014.
Aug 2014
4 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2014
31 Jul · Updates
Members of the Exchange are hereby informed that 628 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. August 04, 2014.24 Jul · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Sun Pharma Advanced Research Company Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sun Pharma Advanced Research Company Limited has vide its letter inter-alia stated," There is no event which will have a bearing on the performance / operations of the Company nor any price sensitivity information of the Company."